Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

FBXL6 promotes bladder cancer progression by stabilizing ENO1 through K63-linked ubiquitination

ABSTRACT: Ubiquitin-mediated post-translational modifications play critical roles in tumor progression, yet their regulatory mechanisms in bladder cancer (BLCA) remain incompletely understood. Here, we identified FBXL6, belonging to the F-box protein family, as a potential oncogenic driver in BLCA through integrative bioinformatic analysis of multiple public datasets and validation in clinical specimens. Functional analyses demonstrated that FBXL6 accelerates both the in vitro proliferation and migration of BLCA cells and the in vivo progression of tumors and metastatic spread. Mechanistically, transcriptomic profiling and metabolic analyses suggested that FBXL6 regulates glycolysis, with particular involvement of the glycolytic enzyme ENO1. While ENO1 mRNA remained largely unchanged upon FBXL6 knockdown, Western blot analysis revealed corresponding changes in ENO1 protein levels, indicating post-transcriptional regulation. Co-immunoprecipitation assays confirmed a physical interaction between FBXL6 and ENO1, and domain-mapping analysis revealed that the leucine-rich repeat (LRR) region of FBXL6 mediates ENO1 binding. Moreover, ubiquitination assays demonstrated that FBXL6 enhances K63-linked polyubiquitination of ENO1, leading to its stabilization. Restoration of ENO1 expression partially rescued the suppressed proliferation and migration induced by FBXL6 knockdown, as demonstrated by rescue assays. Overall, our data support a novel model in which FBXL6 facilitates BLCA progression through K63-linked stabilization of ENO1, highlighting its potential value in targeted therapy for bladder cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE295700 | GEO | 2026/04/26

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

FBXL6 promotes bladder cancer progression by stabilizing ENO1 through K63-linked ubiquitination

Project description:FBXL6 promotes bladder cancer progression by stabilizing ENO1 through K63-linked ubiquitination

| PRJNA1255618 | ENA

Melatonin inhibited tumorigenesis of bladder cancer via suppressing PPARγ/ENO1 mediated glycolysis

Project description:Bladder cancer (BLCA) is one of the most malignant human cancers in the world. The increasingly prominent phenomenon of chemoresistance has become an essential obstacle to clinical treatment for BLCA, and there is an urgent need to explore novel drugs to improve the current clinical status. Melatonin is a well-known natural hormone that showed a potential anti-cancer effect in multiple human cancers. In our study, we comprehensively explored the inhibitory effect of melatonin on BLCA and found that it could suppress the glycolysis process in BLCA cells. Moreover, we discovered that the ninth step enzyme ENO1 of glycolysis was the downstream effector of melatonin and could be a predictive biomarker of BLCA patients.

2022-09-06 | GSE212599 | GEO

Activation of the JNK–ENO1 Axis Promotes Glycolytic Reprogramming and Progression of Retroperitoneal Leiomyosarcoma

Project description:Retroperitoneal leiomyosarcoma (RPLMS) is a highly aggressive malignancy with limited therapeutic options, and its metabolic underpinnings remain poorly understood. In this study, we identified significant activation of glycolytic pathways in RPLMS through RNA-seq analysis, with enolase 1 (ENO1) markedly upregulated in both tumor tissues and patient-derived cell lines. Functional experiments demonstrated that ENO1 knockdown suppresses proliferation, migration, and glycolytic metabolism in RPLMS cells. Mechanistically, JNK signaling was shown to directly promote ENO1 transcription, thereby driving glycolytic reprogramming. Our findings reveal that the JNK–ENO1 axis plays a critical role in RPLMS progression, suggesting that targeting this pathway may represent a promising therapeutic strategy for this devastating disease.

2026-06-01 | GSE315333 | GEO

NOTCH3 Promotes Malignant Progression of Bladder Cancer by Directly Regulating SPP1 and Activating PI3K/AKT Pathway

Project description:The biological role and precise molecular mechanisms of Notch receptor 3 (NOTCH3) in the malignant progression of bladder cancer (BLCA) remain unclear. In this study, we found that NOTCH3 was significantly upregulated and associated with poor prognosis in BLCA patients. Functional experiments demonstrated that NOTCH3 knockdown inhibited BLCA cell proliferation, migration, invasion and significantly suppressed tumor growth and metastasis in vivo as well. Mechanically, chromatin immunoprecipitation and dual-luciferase reporter assays confirmed that NOTCH3 could promote the transcription of secreted phosphoprotein 1(SPP1), a potential downstream target gene of NOTCH3，by binding to the CSL elements in the SPP1 promoter. Moreover, we also found that targeting NOTCH3 inhibited BLCA growth and metastasis by suppressing the SPP1-PI3K/AKT axis. Our study highlights the critical role of NOTCH3-SPP1-PI3K/AKT axis in the malignant progression of BLCA, suggesting that NOTCH3 may be a potential therapeutic target for BLCA.

2024-11-27 | GSE279910 | GEO

YKT6 promotes bladder cancer progression by stabilizing β-Catenin via USP7-mediated deubiquitination

Project description:Bladder cancer (BLCA) remains a highly lethal genitourinary malignancy with complex tumor biology and limited therapeutic strategies. This study investigates the oncogenic role of YKT6, a SNARE protein, in BLCA progression and molecular mechanisms. We demonstrate that YKT6 is significantly upregulated in BLCA tissues and cell lines, correlating with advanced tumor grade, aggressive histology, and poor patient prognosis. Comprehensive transcriptomic and functional analyses reveal that YKT6 promotes BLCA cell proliferation, migration, and metastasis both in vitro and in vivo. Mechanistically, YKT6 activates the Wnt/β-catenin signaling pathway through a novel mechanism involving USP7-mediated deubiquitination of β-catenin. By recruiting USP7, YKT6 inhibits β-catenin’s proteasomal degradation, thereby stabilizing the protein and driving nuclear accumulation. This stabilization leads to increased expression of oncogenic target genes and induces epithelial-mesenchymal transition (EMT). Pharmacological interventions demonstrated that Wnt signaling inhibition reverses YKT6-driven malignant effects, while pathway activation restores tumor progression in YKT6-silenced cells. USP7 knockdown abrogates YKT6-mediated β-catenin stabilization, confirming their functional interdependence. Clinically, the YKT6/USP7/β-catenin axis strongly correlates with poor prognosis, highlighting its potential as a diagnostic and therapeutic target. Our findings unveil YKT6 as a novel regulator of Wnt signaling through USP7-dependent deubiquitination, offering promising insights for precision BLCA therapy.

2025-11-27 | GSE293406 | GEO

ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism

Project description:Enolase 1 (ENO1) is a glycolytic enzyme that plays essential roles in various pathological activities including cancer development. However, the mechanisms underlying ENO1-contributed tumorigenesis are not well explained. Here, we uncover that ENO1, as an RNA-binding protein, binds to the cytosine-uracil-guanine-rich elements of YAP1 messenger RNA to promote its translation. ENO1 and YAP1 positively regulate alternative arachidonic acid (AA) metabolism by inverse regulation of PLCB1 and HPGD (15-hydroxyprostaglandin dehydrogenase). The YAP1/PLCB1/HPGD axis-mediated activation of AA metabolism and subsequent accumulation of prostaglandin E2 (PGE2) are responsible for ENO1-mediated cancer progression, which can be retarded by aspirin. Finally, aberrant activation of ENO1/YAP1/PLCB1 and decreased HPGD expression in clinical hepatocellular carcinoma samples indicate a potential correlation between ENO1-regulated AA metabolism and cancer development. These findings underline a new function of ENO1 in regulating AA metabolism and tumorigenesis, suggesting a therapeutic potential for aspirin in patients with liver cancer with aberrant expression of ENO1 or YAP1.

2023-05-19 | GSE183703 | GEO

ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1

Project description:ENO1 (α-Enolase 1) is a key glycolytic enzyme that catalyzes the dehydratation of 2-phosphoglycerate to phosphoenolpyruvate. It also belongs to a member of the RNA degradosome of Escherichia coli and facilitates RNA degradation, but it’s currently unknown whether ENO1 possesses similar function in eukaryotes. To test this possibility,we performed RNA-seq assays expressing NTC or ENO1 shRNA, respectively.

2021-09-10 | GSE153989 | GEO

ENO1 siRNA knockdown in Human HeLa cells

Project description:HeLa cells were either treated with ENO1 or control siRNAs using the protocol of the RNAiMax reagent (ENO1 pool: SMARTpool ON-TARGETplus L-004034-00-0005 and control pool: ON-TARGETplus non-targeting siRNAs 1-4). Three replicates per condition were produced.

2020-10-27 | E-MTAB-9032 | biostudies-arrayexpress

LncRNA P4HA2-AS1 Drives Renal Interstitial Fibrosis via TRIM32-Mediated K63 Ubiquitination of ULK1 and Autophagic Dysregulation

Project description:Renal interstitial fibrosis (RIF), the central pathological driver of chronic kidney disease (CKD) progression, remains mechanistically incompletely defined. While long non-coding RNAs (lncRNAs) are emerging as critical regulators of CKD, their roles in RIF pathogenesis are poorly understood. Here, we identify the fibrosis-associated lncRNA P4HA2-AS1 as a key modulator of RIF through integrated analyses of unilateral ureteral obstruction (UUO) mice and TGF-β-stimulated human renal tubular epithelial cells (HK-2), combined with RNA sequencing, RNA pull-down, ubiquitination profiling, and autophagic flux assays. P4HA2-AS1 was markedly upregulated in fibrotic kidneys, and its suppression attenuated fibrotic phenotypes in vivo and in vitro while restoring autophagic flux. Mechanistically, P4HA2-AS1 directly binds the E3 ubiquitin ligase TRIM32, impeding its proteasomal degradation. This stabilization enhances TRIM32-mediated K63-linked ubiquitination of ULK1, a master autophagy initiator, leading to aberrant autophagic activation and fibrotic progression. Our study uncovers a previously unrecognized P4HA2-AS1/TRIM32/ULK1 axis that couples dysregulated autophagy to RIF, proposing lncRNA-protein interaction targeting as a therapeutic strategy against renal fibrosis.

2026-01-16 | GSE296844 | GEO

ENO1 influences ATP pool of cytoplasm and lactate homeostasis by regulating glycolysis to promote tumor stemness and metastasis

Project description:This study demonstrated the role of the glycolytic enzyme alpha-enolase (ENO1) on glycolysis and stemness in gastric cancer (GC). High ENO1 expression was associated with poor prognosis and promoted malignant phenotypes and stem-like characteristics in GC. Mechanistically, ENO1 directly stimulated lactate and ATP production by regulating glycolysis, affecting lactate homeostasis and intracellular ATP pools, and co-regulating the AMPK/mTOR and PI3K/AKT signaling pathways. This ultimately drove GC stemness, epithelial-mesenchymal transition (EMT)-related markers, self-renewal, migration, and invasion.

2025-09-27 | GSE307717 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data